Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
PACIFIC trial of durvalumab for stage III NSCLC

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 1267

Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Dr Paz-Ares speaks with ecancer at ESMO 2017 about the outcomes of patients with unresectable advanced lung cancer treated with anti-PD-L1 durvalumab, following chemoradiation.

He reports improved progression free survival compared to placebo, noting that a median overall survival has not yet been reached, and that these results could contribute to the eventual approval of durvalumab in this indication.

For more on this trial, watch Dr Paz-Ares present the results to the Congress here, or read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence